Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...
15h
Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target
We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results